Why Merck is in infectious disease for the long haul

Why Merck is in infectious disease for the long haul

Source: 
BioCentury
snippet: 

Merck is bucking the trend of its biopharma peers by continuing to invest in and build its infectious disease pipeline. With new regulatory pathways in play and novel funding mechanisms for antibiotics starting to take off, the pharma believes its decision to stay the course will be rewarded.